Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for XIAFLEX� (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord... (Source: Bones / Orthopaedics News From Medical News Today)
Read More... [Source: MedWorm: Dupuytren's Contracture - Posted by FreeAutoBlogger]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment